CAMBRIDGE, Mass. , Sept. 14, 2020 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the appointment of David Hava , Ph.D. as Chief Scientific Officer. Dr....

CAMBRIDGE, Mass. , Sept. 8, 2020 /PRNewswire/ --  Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that Aoife Brennan , M.B. Ch.B., Synlogic's president and chief executive officer, and other members of...

- Synlogic ends 2Q2020 with $109.1 million in cash, cash equivalents and investments supporting projected runway into 2022 - Company continues to advance multiple clinical stage Synthetic Biotic medicines - Management to host conference call and webcast at 8:00 am ET today - CAMBRIDGE,...

CAMBRIDGE, Mass. , July 31, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that Aoife Brennan , M.B. Ch.B., Synlogic's president and chief executive officer, and other members of...

CAMBRIDGE, Mass. , July 30, 2020 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the promotion of Antoine 'Tony' Awad to the position of Chief Operating Officer....

CAMBRIDGE, Mass. , July 28, 2020 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the Company will release its second quarter 2020 financial results before the market opens on Thursday,...

- SYNB1891 is currently being evaluated in a Phase 1 clinical trial in patients with advanced solid tumors or lymphoma - CAMBRIDGE, Mass. , June 1, 2020 /PRNewswire/ --  Synlogic, Inc., (Nasdaq: SYBX) a clinical stage company applying synthetic biology to beneficial microbes to develop novel,...

Live Webcast Scheduled to Begin at 12.30 pm ET Today CAMBRIDGE, Mass. , May 27, 2020 /PRNewswire/ --  Synlogic (Nasdaq: SYBX) today will host its first Virtual R&D Event which will include presentations from members of the Synlogic executive team providing an in-depth review of Synlogic's Synthetic...

CAMBRIDGE, Mass. , May 21, 2020 /PRNewswire/ --  Synlogic (Nasdaq: SYBX) announced today that the company will host a Virtual R&D Event at 12:30 pm ET on Wednesday, May 27th, 2020 . The event will provide an in-depth review of Synlogic's Synthetic Biotic platform and programs for the treatment of...

CAMBRIDGE, Mass. , May 21, 2020 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the termination of its collaboration with AbbVie, a global, research-based biopharmaceutical...

-Cash and investments of $114 million provide runway into 2022 - -Company will host virtual R&D event highlighting progress in its Synthetic Biotic platform and programs on Wednesday, May 27, 2020 - - Company will host a conference call at 8:00 am ET today - CAMBRIDGE, Mass....

CAMBRIDGE, Mass. , May 4, 2020 /PRNewswire/ --  Synlogic, Inc.  (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, announced today that the Company will release its first quarter 2020 financial results before the market...